VIDEO: What’s new with perioperative anti-inflammatories in cataract surgery

ByJohn A. Hovanesian, MD, FACS

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — In his presentation at OSN New York 2019, John A. Hovanesian, MD, FACS, of Harvard Eye Associates in Laguna Hills, California, discusses new steroid delivery options such as Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) and Dexycu (dexamethasone intraocular suspension 9%, EyePoint Pharmaceuticals), as well as other new steroids and NSAIDs in cataract surgery. – by David W. Mullin